Refine
Year of publication
- 2011 (5) (remove)
Document Type
- Article (5)
Has Fulltext
- yes (5)
Is part of the Bibliography
- no (5)
Keywords
Institute
- Medizin (3)
- Frankfurt Institute for Advanced Studies (FIAS) (1)
- Informatik (1)
- Physik (1)
Rapidity and transverse momentum dependence of inclusive J/ψ production in pp collisions at √s=7 TeV
(2011)
The ALICE experiment at the LHC has studied inclusive J/ψ production at central and forward rapidities in pp collisions at √s=7 TeV. In this Letter, we report on the first results obtained detecting the J/ψ through the dilepton decay into e+e− and μ+μ− pairs in the rapidity ranges |y|<0.9 and 2.5<y<4, respectively, and with acceptance down to zero pT. In the dielectron channel the analysis was carried out on a data sample corresponding to an integrated luminosity Lint=5.6 nb−1 and the number of signal events is NJ/ψ=352±32(stat.)±28(syst.); the corresponding figures in the dimuon channel are Lint=15.6 nb−1 and NJ/ψ=1924±77(stat.)±144(syst.). The measured production cross sections are σJ/ψ(|y|<0.9)=10.7±1.0(stat.)±1.6(syst.)−2.3+1.6(syst.pol.)μb and σJ/ψ(2.5<y<4)=6.31±0.25(stat.)±0.76(syst.)−1.96+0.95(syst.pol.)μb. The differential cross sections, in transverse momentum and rapidity, of the J/ψ were also measured.
Tierfilme und -reportagen haben Konjunktur, neue Bildtechnologien ermöglichen immer differenziertere Einblicke in Verhaltens- und Lebensweisen bekannter und unbekannter Tierarten. Wir fühlen uns als teilnehmende Beobachter in scheinbar gewagtester Nähe. Das "Privatleben" der Tiere wird bis in den letzten Winkel verfolgt, die Entdeckung der Tierindividualitäten schreitet voran, Tiere bekommen ein Schicksal und wecken Empathie, der vor über 2000 Jahren entstandene Tier-Mensch-Verwandtschafts-Topos, dem noch jeder Gedanke an die Abstammung der Arten fern lag, wird neu belebt. Doch das kulturelle Interesse am Tier erschöpft sich nicht im Fasziniertsein durch perfekt visualisierte Verhaltensstudien oder durch neueste Lesarten der Tiermetaphorik, in der es stets weniger um Tiere als um Menschen geht. Der historische Wandel der menschlichen Tierbeziehung wird in der Tierethik reflektiert.
Seit der Antike umstrittene kognitive Fähigkeiten verschiedener Tierarten bilden heute einen einzelwissenschaftlich fundierten philosophischen Diskussions- und Forschungsgegenstand ("Der Geist der Tiere"). Die Biosemiotik macht große Fortschritte, der Tier-Mensch-Vergleich - bereits ein Kernstück antiker Anthropologie und Ethik - erfährt eine tiefgreifende Umwertung. Dabei steht nicht mehr von vornherein der Mensch im Mittelpunkt; vielmehr wird versucht, das Animalische in seiner Artenvielfalt als eine vielgestaltige eigene Lebensform zu beschreiben; diese ist nicht länger an Maßstäben einer Anthropozentrik zu messen, die im innersten teleologisch geblieben ist. Der Tier-Mensch-Vergleich wird heute nicht mehr so einseitig und ausschließlich auf kognitive Fähigkeiten bezogen. Vielmehr werden weitere Aspekte wie Emotionalität, Wertungs- bzw. Präferenzverhalten, moralanaloge Verhaltensweisen, Antriebsstrukturen, Soziabilität, Zeichenverhalten mit einbezogen. Diese Komplexität der Vergleichspunkte oder Vergleichseinheiten war erst mit dem neuzeitlichen Rationalismus immer mehr eingeschränkt worden. Die gegenwärtig wiedergewonnene Komplexität lässt nach historischen Vorbildern Ausschau halten; da verwundert es nicht, wenn eine Anthropologie ins Blickfeld rückt, die im Tier-Mensch-Vergleich einen ihrer wichtigsten Ausgangspunkte hatte: die antike Anthropologie.
HDL, through sphingosine-1-phosphate (S1P), exerts direct cardioprotective effects on ischemic myocardium. It remains unclear whether other HDL-associated sphingophospholipids have similar effects. We therefore examined if HDL-associated sphingosylphosphorylcholine (SPC) reduces infarct size in a mouse model of transient myocardial ischemia/reperfusion. Intravenously administered SPC dose-dependently reduced infarct size after 30 minutes of myocardial ischemia and 24 hours reperfusion compared to controls. Infarct size was also reduced by postischemic, therapeutical administration of SPC. Immunohistochemistry revealed reduced polymorphonuclear neutrophil recruitment to the infarcted area after SPC treatment, and apoptosis was attenuated as measured by TUNEL. In vitro, SPC inhibited leukocyte adhesion to TNFα-activated endothelial cells and protected rat neonatal cardiomyocytes from apoptosis. S1P3 was identified as the lysophospholipid receptor mediating the cardioprotection by SPC, since its effect was completely absent in S1P3-deficient mice. We conclude that HDL-associated SPC directly protects against myocardial reperfusion injury in vivo via the S1P3 receptor.
Background: Data on the economic impact of Lyme borreliosis (LB) on European health care systems is scarce. This project focused on the epidemiology and costs for laboratory testing in LB patients in Germany.
Materials and Methods: We performed a sentinel analysis of epidemiological and medicoeconomic data for 2007 and 2008. Data was provided by a German statutory health insurance (DAK) company covering approx. 6.04 million members. In addition, the quality of diagnostic testing for LB in Germany was studied.
Results: In 2007 and 2008, the incident diagnosis LB was coded on average for 15,742 out of 6.04 million insured members (0.26%). 20,986 EIAs and 12,558 immunoblots were ordered annually for these patients. For all insured members in the outpatient sector, a total of 174,820 EIAs and 52,280 immunoblots were reimbursed annually to health care providers (cost: 2,600,850€). For Germany, the overall expected cost is estimated at 51,215,105€. However, proficiency testing data questioned test quality and standardization of diagnostic assays used.
Conclusion: Findings from this study suggest ongoing issues related to care for LB and may help to improve future LB disease management.
Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting.
Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators.
Results: A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician's visual analogue scale; mean improvement from baseline of 12.1 mm).
Conclusions: Data from this registry indicate that rituximab is a commonly employed, well-tolerated therapy with potential beneficial effects in standard of care-refractory autoimmune diseases, and support the results from other open-label, uncontrolled studies.